Table 2.
General populations: prevalence range (%) [# of studies] | Clinical populations: prevalence range (%) [# of studies] | Undergoing intervention (severe): prevalence range (%) [# of studies] | |
---|---|---|---|
WHO region | |||
African | No studies found | No studies found | No studies found |
Eastern Mediterranean | 9.20 [1] | No studies found | No studies found |
European | 0.21–33.33 [25] | 9.38–91.00 [2] | 68.60 [1] |
Region of the Americas | 0.25–38.90 [11] | 3.20 [1] | 76.60 [3] |
South-East Asia | No studies found | No studies found | No studies found |
Western Pacific | 1.20–57.50 [22] | 4.00–69.00 [7] | 50.42–79.25 [2] |
Multiple regions | 0.56–5.28 [2]* | No studies found | No studies found |
Gender/sex | |||
Male | 0.21–57.50 [25] | 33.91–91.00 [3] | 50.42–79.25 [2] |
Female | 0.25–26.09 [21] | 69.00 [1] | No studies found |
Age groups | |||
Children (0–19 years old) | 0.26–38.00 [20] | 7.93–11.44 [2] | 68.60–79.25 [2] |
Adolescents (10–19 years old) | 0.26–38.00 [17] | 7.93–11.44 [2] | 68.60–79.25 [2] |
Adults (18 years and older) | 0.21–55.77 [27] | 3.20–69.00 [6] | 76.60 [3] |
General: Populations that were not seeking treatment for GD or IGD, did not have GD or IGD at recruitment, and were not undergoing treatment for GD or IGD. Clinical: Populations who sought treatment, and populations with GD or IGD at recruitment. Severe: Populations undergoing treatment for GD or IGD. WHO World Health Organization
#Number
*Studies covered multiple geographic regions